External preparation for skin
The skin external preparation combines niacinamide with D-pantothenyl alcohol, 3-O-ethyl ascorbic acid, and other ingredients encapsulated in liposomes to address the lack of an excellent moisturizing effect and feel in existing niacinamide-based preparations, achieving enhanced skin hydration and firmness.
Patent Information
- Application Number
- PCT/JP2023/018955
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Existing skin external preparations using niacinamide do not achieve an excellent moisturizing effect and feel of use, despite its known benefits for skin health.
A skin external preparation containing niacinamide, D-pantothenyl alcohol, 3-O-ethyl ascorbic acid, pine bark extract, and at least one selected from glutathione and ceramides, encapsulated in liposomes with hydrogenated soybean phospholipids, along with additional antioxidants, humectants, anti-inflammatory agents, whitening agents, vitamins, and peeling agents, to enhance moisturization and skin feel.
The formulation provides an excellent moisturizing effect, smoothness during application, and improved skin clarity and firmness, increasing the moisture content of the stratum corneum and enhancing the overall skin feel.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
topical skin preparations
[0001] The present invention relates to an external preparation for skin.
[0002] Various active ingredients have been proposed for topical skin preparations, and cosmetics and pharmaceuticals incorporating these active ingredients are now on the market. Examples include cell-activating ingredients such as α-hydroxycarboxylic acids; extracellular matrix components such as collagen, elastin, hyaluronic acid or salts thereof; and moisturizers such as urea. Furthermore, plant-derived antioxidants and moisturizers have also been proposed. For example, Patent Document 1 describes that topical skin preparations containing niacinamide and an extract of the fruit of Ziziphus jujuba (Rhamnaceae) as active ingredients can improve the skin's barrier function, prevent and improve dry skin, and prevent and improve skin thinning. Patent Document 1 also describes an essence containing niacinamide and ceramide. Patent Document 2 also describes a topical skin preparation for wrinkle reduction containing D-pantothenyl alcohol and niacinamide.
[0003] Japanese Patent Application Publication No. 2022-163643 Japanese Patent Application Publication No. 2021-063076
[0004] However, no topical skin preparation using niacinamide and having excellent moisturizing effect and a pleasant feeling when used has been available. An object of the present invention is to provide a topical skin preparation using niacinamide and having excellent moisturizing effect and a pleasant feeling when used.
[0005] The present invention provides the following [1] to [4]. [1] A topical skin preparation comprising niacinamide as a composition containing the following (A), (B), (C), (D), (E), and (F), wherein (C), (D), and (E) are encapsulated in liposomes containing (F) hydrogenated soybean phospholipid. (A) niacinamide. (B) D-pantothenyl alcohol. (C) 3-O-ethyl ascorbic acid. (D) pine bark extract. (E) at least one selected from glutathione and ceramides. (F) hydrogenated soybean phospholipid. [2] The topical skin preparation according to [1], further comprising (G) at least one selected from antioxidants, moisturizers, anti-inflammatory agents, whitening agents, vitamins, and peeling agents. [3] The topical skin preparation according to [2], wherein (G) is one or more selected from the group consisting of bilberry leaf extract, astaxanthin, Centella asiatica leaf extract, bisglyceryl ascorbate, tocopherol, and lactic acid. [4] The topical skin preparation according to any one of [1] to [3], wherein the content of (A) niacinamide in the composition is 5% by mass or more.
[0006] The present invention can provide an external skin preparation using niacinamide, which has an excellent moisturizing effect and a pleasant feel when used.
[0007] A preferred embodiment of the present invention is described below. In the present invention, "feel during use" refers to smoothness upon application and improved skin clarity and firmness after use. Furthermore, in the present invention, moisturizing effects refer to an effect of increasing the moisture content of stratum corneum. The present invention provides an external skin preparation, which is a composition containing the above-mentioned (A), (B), (C), (D), (E), and (F), wherein (C), (D), and (E) are encapsulated in liposomes containing (F) hydrogenated soybean phospholipid. Liposomes are closed vesicles formed by a lipid bilayer membrane containing lipids such as lecithin, and have an aqueous phase (internal aqueous phase) within the closed vesicle space. Furthermore, liposomes often exist in a dispersed state in an aqueous solution (external aqueous phase) outside the closed vesicles. In this specification, "a given component being encapsulated in a liposome" refers to the presence of at least a portion of the component in the liposome membrane or the internal aqueous phase within the liposome, rather than the component being present only in the external aqueous phase.
[0008] (A) Niacinamide By containing (A) niacinamide in the presence of (B) to (F), the topical skin preparation of the present invention can enhance the moisturizing effect and obtain improved usability, such as smoothness upon application and firmness of the skin after use. Niacinamide is also known as nicotinamide. Niacinamide may be an extract extracted from natural products such as rice bran, a synthetic product synthesized by a known method, or a commercially available product. Specifically, nicotinamide listed in the 17th edition of the Japanese Pharmacopoeia can be used.
[0009] (A) Niacinamide may be encapsulated in liposomes containing (F) hydrogenated soybean phospholipids, or may be present in the external aqueous phase outside the liposomes.
[0010] In order to further improve the effect of excellent moisturizing effect, smoothness when applied, and excellent firmness of skin after use, (A) niacinamide is preferably contained in the skin external preparation of the present invention at 1% by mass or more, more preferably at 2% by mass or more.In particular, in order to improve moisturizing effect, (A) niacinamide is more preferably contained in the skin external preparation at 3% by mass or more, particularly preferably at 4% by mass or more, and most preferably at 5% by mass or more.The upper limit of the amount of (A) niacinamide in the skin external preparation is preferably below 15% by mass, in order to obtain the skin external preparation with excellent feeling of use, more preferably below 12% by mass, most preferably below 10% by mass.
[0011] (B) D-Pantothenyl Alcohol The topical skin preparation of the present invention contains (B) D-pantothenyl alcohol in the presence of (A), (C) to (F), thereby achieving excellent moisturizing effects, smoothness upon application, and excellent skin clarity and firmness after use. As the D-pantothenyl alcohol, commercially available products can be used, and specifically, D-pantothenyl alcohol listed in the Quasi-drug Raw Materials Standards 2021 can be used.
[0012] In the topical skin preparation of the present invention, the amount of (B) D-pantothenyl alcohol in the topical skin preparation is preferably 0.01% by mass or more in order to enhance the effects of the present invention achieved by using (B) D-pantothenyl alcohol. From this viewpoint, the amount of (B) D-pantothenyl alcohol in the topical skin preparation is even more preferably 0.05% by mass or more, and particularly preferably 0.1% by mass or more. From the same viewpoint, the amount of (B) D-pantothenyl alcohol in the topical skin preparation is preferably 20% by mass or less, even more preferably 10% by mass or less, and particularly preferably 5% by mass or less.
[0013] (B) D-pantothenyl alcohol may be encapsulated in the liposome containing (F) hydrogenated soybean phospholipid, or may be present in the external aqueous phase outside the liposome.
[0014] In the topical skin preparation of the present invention, the amount of (B) D-pantothenyl alcohol is preferably 0.1 to 100 parts by mass per 100 parts by mass of (A) niacinamide, in order to further improve the effects of the present invention. From this viewpoint, the amount of (B) D-pantothenyl alcohol is even more preferably 1 part by mass or more, and particularly preferably 5 parts by mass or more, per 100 parts by mass of (A) niacinamide. From the viewpoint of further improving the effects of the present invention, the amount of (B) D-pantothenyl alcohol is even more preferably 80 parts by mass or less, and particularly preferably 50 parts by mass or less, per 100 parts by mass of (A) niacinamide.
[0015] (C) 3-O-ethyl ascorbic acid The topical skin preparation of the present invention contains (C) 3-O-ethyl ascorbic acid in the presence of (A), (B), and (D) to (F), thereby enhancing the moisturizing effect and also improving the smoothness upon application and the firmness of the skin after use.
[0016] The 3-O-ethyl ascorbic acid is not particularly limited as long as it is used as a component of a pharmaceutical, quasi-drug, or cosmetic skin preparation. Synthetic 3-O-ethyl ascorbic acid can be used. Examples of synthesis methods include ethoxylating the hydroxyl group at the 3-position of ascorbic acid, as described in, for example, JP-A-8-134055. Commercially available 3-O-ethyl ascorbic acid can also be used as is.
[0017] (C) 3-O-ethyl ascorbic acid is encapsulated in liposomes containing (F) hydrogenated soybean phospholipid. This improves the stability of (C) 3-O-ethyl ascorbic acid in the topical skin preparation of the present invention, thereby enhancing the moisturizing effect as well as the effects of improving smoothness upon application and firmness of skin after use. The encapsulation of component (C) in liposomes containing (F) hydrogenated soybean phospholipid can be confirmed by removing the liposomes from the topical skin preparation and conducting confirmation tests on each component. The presence of component (C) within the liposomes can be confirmed, for example, by removing the external aqueous phase outside the liposomes using gel filtration chromatography, followed by liquid chromatography or the like.
[0018] In the topical skin preparation of the present invention, the amount of (C) 3-O-ethyl ascorbic acid is preferably 0.00001% by mass or more in the topical skin preparation, in order to enhance the effects of the present invention achieved by using (C) 3-O-ethyl ascorbic acid. From this viewpoint, the amount of (C) 3-O-ethyl ascorbic acid in the topical skin preparation is even more preferably 0.00005% by mass or more, and particularly preferably 0.0001% by mass or more. From the same viewpoint, the amount of (C) 3-O-ethyl ascorbic acid in the topical skin preparation is preferably 10% by mass or less, even more preferably 5% by mass or less, and particularly preferably 1% by mass or less.
[0019] In the topical skin preparation of the present invention, the amount of (C) 3-O-ethylascorbic acid is preferably 0.0001 to 50 parts by mass relative to 100 parts by mass of (A) niacinamide, in order to further improve the effects of the present invention. From this viewpoint, the amount of (C) 3-O-ethylascorbic acid is even more preferably 0.001 part by mass or more, and particularly preferably 0.005 part by mass or more, relative to 100 parts by mass of (A) niacinamide. From the viewpoint of further improving the effects of the present invention, the amount of (C) 3-O-ethylascorbic acid is even more preferably 30 parts by mass or less, and particularly preferably 10 parts by mass or less, relative to 100 parts by mass of (A) niacinamide.
[0020] (D) Pine bark extract The topical skin preparation of the present invention contains (D) pine bark extract in the presence of (A) to (C), (E) and (F), thereby effectively enhancing the moisturizing effect, as well as improving the smoothness upon application and the firmness of the skin after use.
[0021] In the present invention, pines that can be used as the source of the pine bark extract (D) include, but are not limited to, plants belonging to the Pinales order, such as French maritime pine, larch, Japanese black pine, Japanese red pine, Pinus sieboldii, Pinus sieboldii, Pinus sieboldii, Pinus koraiensis, Pinus sieboldii, Pinus sieboldii, Pinus palustris, and Pinus sieboldii of Quebec, Canada. Among these, French maritime pine (Pinus pinaster), a maritime pine growing on the Atlantic coast of southern France, is preferred, as its safety as a topical skin preparation has been confirmed and it contains high concentrations of antioxidants such as catechins.
[0022] (D) Pine bark extract is obtained by extracting pine bark with a solvent. Examples of the solvent include water, organic solvents, and aqueous organic solvents (aqueous alcohols such as aqueous ethanol). The organic solvent used for extraction is typically an organic solvent acceptable for extracting natural product components, such as monohydric alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and 2-butanol; glycols such as propylene glycol; polyhydric alcohols such as glycerin; butane; acetone; hexane; cyclohexane; aqueous ethanol; aqueous propylene glycol; ethyl methyl ketone; methyl acetate; ethyl acetate; diethyl ether; dichloromethane; edible oils and fats; 1,1,1,2-tetrafluoroethane; and 1,1,2-trichloroethene. These solvents may be used alone or in combination. The temperature during extraction may be adjusted appropriately from room temperature to a temperature below the boiling point of the extraction solvent. In the present invention, from the viewpoint of efficiently improving the moisturizing effect, smoothness upon application, and firmness of the skin after use, at least one selected from water, aqueous ethanol, and aqueous propylene glycol is preferably used.
[0023] The extraction method is not particularly limited as long as it is a method generally acceptable for extracting natural product components, but examples include solid-liquid extraction methods such as thermal extraction and supercritical fluid extraction. Thermal extraction involves contacting a test substance with a solvent and treating the solvent at a temperature below the boiling point of the solvent to extract components contained in the test substance into the solvent. Reflux extraction may also be used. Supercritical fluid extraction involves extraction using a supercritical fluid, which is a fluid in a state exceeding the gas-liquid critical point (critical temperature, critical pressure) of a substance. Examples of supercritical fluids include carbon dioxide, ethylene, propane, and nitrous oxide (laughing gas). Entrainer addition may also be used as a supercritical fluid extraction method. In this method, approximately 2 to 20 wt. % of ethanol, propanol, n-hexane, acetone, toluene, or other aliphatic lower alcohols, aliphatic hydrocarbons, aromatic hydrocarbons, or ketones is added to the extraction fluid, and supercritical fluid extraction is performed using this fluid. In addition to the above-mentioned extraction methods, extraction from pine bark may also be performed by a liquid carbon dioxide batch method, a liquid carbon dioxide reflux method, a supercritical carbon dioxide reflux method, etc. Supercritical fluid extraction involves an extraction step in which the target component is extracted with a supercritical fluid, and a separation step in which the target component is separated from the supercritical fluid. The separation step may involve extraction and separation by pressure change, extraction and separation by temperature change, or extraction and separation using an adsorbent or absorbent.
[0024] (D) Pine bark extract may be in liquid form, but it can also be used as a paste or dry powder. When it is made into a paste or dry powder, it may be produced using only the extract or may be processed together with an excipient. The pine bark extract obtained by extraction may be purified by ultrafiltration, a column method using an adsorptive carrier (Diaion HP-20, Sephadex-LH20, chitin, etc.), a batch method, or the like.
[0025] The pine bark extract to be added to the topical skin preparation is preferably in powder form, more preferably in dry powder form, from the viewpoints of storage stability and processability. The drying method is not particularly limited, and examples include drying the solvent-containing pine bark extract by heating, sun drying, hot air drying, freeze-drying, or reduced pressure. Alternatively, the solid pine bark extract may be pulverized.
[0026] The pine bark extract may be commercially available, and examples of commercially available pine bark extract include Flavangenol (registered trademark; Toyo Shinyaku Co., Ltd.).
[0027] The pine bark extract (D) is encapsulated in liposomes containing hydrogenated soybean phospholipid (F). This improves the stability of the pine bark extract (D) in the topical skin preparation of the present invention, enhancing the moisturizing effect of the topical skin preparation as well as enhancing the effects of smoothness upon application and firmness of the skin after use. The presence of the component (D) in the liposomes can be confirmed by, for example, confirming the presence of polyphenols derived from the component (D) by liquid chromatography after removing the liposomes.
[0028] In the topical skin preparation of the present invention, the amount of (D) pine bark extract in the topical skin preparation is preferably 0.000001% by mass or more in order to enhance the effects of the present invention achieved by using (D) pine bark extract. From this perspective, the amount of (D) pine bark extract in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more. From the same perspective, the amount of (D) pine bark extract in the topical skin preparation is preferably 10% by mass or less, even more preferably 5% by mass or less, and particularly preferably 1% by mass or less.
[0029] In the topical skin preparation of the present invention, the amount of (D) pine bark extract is preferably 0.0001 to 10 parts by mass per 100 parts by mass of (A) niacinamide, in order to further improve the effects of the present invention. From this perspective, the amount of (D) pine bark extract is even more preferably 0.0005 parts by mass or more, and particularly preferably 0.001 parts by mass or more, per 100 parts by mass of (A) niacinamide. In order to further improve the effects of the present invention, the amount of (D) pine bark extract is even more preferably 8 parts by mass or less, and particularly preferably 5 parts by mass or less, per 100 parts by mass of (A) niacinamide. The amount of each of the above (D) components can be the amount of solid content.
[0030] (E) At least one selected from glutathione and ceramides The topical skin preparation of the present invention contains (E) at least one selected from glutathione and ceramides, which not only effectively enhances the moisturizing effect but also improves the smoothness upon application and the firmness of the skin after use.
[0031] The glutathione may be reduced glutathione, oxidized glutathione, or a mixture thereof, but reduced glutathione is preferred because it is expected to exert an antioxidant effect.
[0032] Among ceramides, examples of ceramides that can be used include human ceramides such as ceramide 1, ceramide 2, and ceramide 3, as well as animal-derived ceramides extracted from the brain, spinal cord, etc. of cows, horses, pigs, etc., and plant-derived ceramides extracted from wheat, rice, soybeans, spinach, corn, konjac, pineapple, etc. Furthermore, the ceramide used in the present invention may be a glycoceramide, and specific examples include those bound to monosaccharides such as galactosylceramide and glucosylceramide, and those bound to oligosaccharides.
[0033] In the topical skin preparation of the present invention, it is preferable to use human ceramides, such as N-stearoylphytosphingosine ("ceramide NP" or "ceramide 3"), N-oleoylphytosphingosine ("ceramide NP" or "ceramide 3"), N-stearoyldihydrosphingosine ("ceramide NG" or "ceramide 2"), stearoyloxyheptacosanoylphytosphingosine ("ceramide EOP" or "ceramide 1"), and hydroxysphingosine ("ceramide EOP" or "ceramide 2"). At least one selected from cystearyl phytosphingosine ("ceramide AP" or "ceramide 6") is preferred, and among these, it is preferred to use at least one selected from N-stearoyl phytosphingosine ("ceramide NP" or "ceramide 3"), N-stearoyl dihydrosphingosine ("ceramide NG" or "ceramide 2"), and hydroxystearyl phytosphingosine ("ceramide AP" or "ceramide 6").
[0034] At least one selected from glutathione (E) and ceramides is encapsulated in liposomes containing hydrogenated soybean phospholipids (F). This improves the stability of glutathione (E) and ceramides in the topical skin preparation of the present invention, thereby enhancing the moisturizing effect and enhancing the effects of smoothness upon application and firmness of the skin after use. The presence of component (E) in the liposomes can be confirmed by, for example, IR (infrared spectroscopy) after removing the liposomes from the topical skin preparation.
[0035] When the topical skin preparation of the present invention contains glutathione, its amount is preferably 0.000001% by mass or more in the topical skin preparation, in order to enhance the effect of the present invention by using glutathione.From this point of view, the amount of glutathione in the topical skin preparation is more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more.Furthermore, from the same point of view, the amount of glutathione in the topical skin preparation is preferably 10% by mass or less, more preferably 5% by mass or less, and particularly preferably 1% by mass or less.
[0036] When glutathione is contained in the topical skin preparation of the present invention, the amount thereof is preferably 0.01 to 50 parts by mass relative to 100 parts by mass of (A) niacinamide, in order to further improve the effects of the present invention. From this viewpoint, the amount of glutathione is even more preferably 0.05 parts by mass or more, and particularly preferably 0.1 parts by mass or more, relative to 100 parts by mass of (A) niacinamide. From the viewpoint of further improving the effects of the present invention, the amount of (C) glutathione is even more preferably 30 parts by mass or less, and particularly preferably 10 parts by mass or less, relative to 100 parts by mass of (A) niacinamide.
[0037] When the skin external preparation of the present invention contains ceramides, its amount is preferably 0.000001% by mass or more in the skin external preparation, in order to make the effect of the present invention by using ceramides excellent.From this point of view, the amount of ceramides in the skin external preparation is more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more.In addition, from the same point of view, the amount of ceramides in the skin external preparation is preferably 0.01% by mass or less, more preferably 0.005% by mass or less, and particularly preferably 0.001% by mass or less.
[0038] When the topical skin preparation of the present invention contains ceramides, the amount thereof is preferably 0.00001 to 1 part by mass relative to 100 parts by mass of (A) niacinamide, in order to further improve the effects of the present invention. From this viewpoint, the amount of ceramides is even more preferably 0.00005 parts by mass or more, and particularly preferably 0.0001 parts by mass or more, relative to 100 parts by mass of (A) niacinamide. From the viewpoint of further improving the effects of the present invention, the amount of ceramides is even more preferably 0.1 parts by mass or less, and particularly preferably 0.01 parts by mass or less, relative to 100 parts by mass of (A) niacinamide.
[0039] In the present invention, it is most preferable to use both (E) glutathione and ceramides in order to further enhance the moisturizing effect.
[0040] (F) Hydrogenated Soybean Phospholipid In the present invention, the topical skin preparation contains liposomes containing (F) hydrogenated soybean phospholipid as a membrane component, and the liposomes encapsulate (C) 3-O-ethyl ascorbic acid, (D) pine bark extract, and (E) at least one selected from glutathione and ceramides. This effectively enhances the moisturizing effect of the topical skin preparation, as well as the effects of improving smoothness upon application and firmness of the skin after use. This is thought to be because the encapsulation of useful ingredients such as (C) 3-O-ethyl ascorbic acid, (D) pine bark extract, and (E) glutathione or ceramides in the liposomes increases the penetration of the useful ingredients into the skin.
[0041] (F) Liposomes using hydrogenated soybean phospholipids are particularly important for maintaining the emulsification stability of topical skin preparations. The hydrogenated soybean phospholipid used in the present invention may be hydrogenated soybean lecithin, in which the unsaturated carbon chains in soybean phospholipids such as soybean lecithin have been converted to saturated bonds by hydrogenation.
[0042] Liposomes containing (F) hydrogenated soybean phospholipid as a membrane component preferably have an average particle diameter of 30 nm to 300 nm, which can improve stability over time, increase the encapsulation rate of (C) to (E), and improve the permeability of the liposomes into the skin, etc. From these perspectives, the average particle diameter of the liposomes is preferably 40 nm to 250 nm, and more preferably 50 nm to 200 nm. The average particle diameter of the liposomes can be measured using commercially available particle size distribution meters such as laser diffraction particle size distribution meters and light scattering photometers, but is preferably measured using a dynamic light scattering particle size distribution analyzer. As the dynamic light scattering particle size distribution analyzer, a Zetasizer S manufactured by Malvern Instruments can be used.
[0043] In the present invention, liposomes encapsulating (C) to (E) can be prepared as follows. First, hydrogenated soybean phospholipid (F) is mixed with an organic solvent to prepare a phospholipid solution. A dihydric alcohol is preferably used as the organic solvent. To successfully obtain liposomes encapsulating (C) to (E), the phospholipid solution is preferably prepared at 80 to 90°C, more preferably at 85 to 90°C.
[0044] To successfully obtain liposomes encapsulating (C) to (E), the amount of organic solvent used to prepare the phospholipid solution is preferably 180 to 400 parts by mass, more preferably 200 to 350 parts by mass, per 100 parts by mass of hydrogenated soybean phospholipid (F). To successfully obtain liposomes with a high encapsulation rate of components (C) to (E), it is desirable to include an oily component such as a sterol in the phospholipid solution before adding the aqueous phase described below. Furthermore, to successfully obtain liposomes encapsulating (C) to (E), the amount of hydrogenated soybean phospholipid (F) per 100 parts by mass of the total amount of (C) to (E) may be any amount that corresponds to the ratio of (C) to (E) to (F) in the topical skin preparation described below. Of these, 80 to 250 parts by mass is particularly preferred, and 100 to 220 parts by mass is even more preferred.
[0045] Next, an aqueous phase containing (C), (D), and (E) is prepared. The amount of water used to prepare the aqueous phase may be appropriately adjusted to an appropriate amount in order to disperse (C), (D), and (E) and encapsulate the phospholipids described below. The amount may be 1,000 to 5,000,000 parts by mass, or 4,000 to 2,000,000 parts by mass per 100 parts by mass of the total amount of (C), (D), and (E). To successfully obtain liposomes with an excellent encapsulation rate of components (C) to (E), the aqueous phase containing (C), (D), and (E) is preferably prepared at 80 to 90°C, more preferably at 85 to 90°C. (C), (D), and (E) may be added to water at the same time or at different times.
[0046] Next, the phospholipid solution and the aqueous phase are mixed. To successfully obtain liposomes with an excellent encapsulation rate of components (C) to (E), this mixing is preferably carried out at 80 to 90°C, and more preferably at 85 to 90°C. This mixing can also be carried out by gentle stirring using a propeller or the like.
[0047] In the above-mentioned production method, component (A) is preferably added to the topical skin preparation after the preparation of liposomes, and component (B) is preferably added to the topical skin preparation after the preparation of liposomes.
[0048] The content of (F) hydrogenated soybean phospholipid in the topical skin preparation is preferably 0.001% by mass or more, more preferably 0.01% by mass or more, and particularly preferably 0.05% by mass or more, from the viewpoint of successfully obtaining liposomes with an excellent encapsulation rate of components (C) to (E). Furthermore, the content of (F) hydrogenated soybean phospholipid in the topical skin preparation is preferably 20% by mass or less, more preferably 10% by mass or less, and even more preferably 5% by mass or less, from the viewpoint of obtaining a topical skin preparation that is smooth to the touch and has excellent skin penetration.
[0049] The content of hydrogenated soybean phospholipid (F) in the topical skin preparation is preferably 0.01 parts by mass or more per part by mass of the total amount of (C), (D), and (E), from the viewpoint of successfully obtaining a liposome membrane with an excellent encapsulation rate of components (C) to (E), more preferably 0.05 parts by mass or more, and particularly preferably 0.1 parts by mass or more. Furthermore, the content of hydrogenated soybean phospholipid (F) in the topical skin preparation is preferably 20 parts by mass or less per part by mass of the total amount of (C), (D), and (E), from the viewpoint of obtaining a topical skin preparation that is smooth in use and has excellent skin penetration, more preferably 15 parts by mass or less, and even more preferably 10 parts by mass or less.
[0050] The topical skin preparation of the present invention preferably further contains, as a component other than the components (A) to (F), at least one selected from (G1) antioxidants, (G2) moisturizing agents, (G3) anti-inflammatory agents, (G4) whitening agents, (G5) vitamins, and (G6) peeling agents, in order to enhance the moisturizing effect and effectively improve the smoothness upon application and the transparency and firmness of the skin after use. Here, a peeling agent refers to an agent used to increase the flexibility of keratin and remove it.
[0051] Examples of (G1) antioxidants include ubiquinone and astaxanthin, with astaxanthin being particularly preferred from the viewpoint of enhancing moisturizing effect and usability. Astaxanthin is known to be contained in Haematococcus algae, crustaceans such as shrimp and crab, and salmon. While there are no particular limitations on the astaxanthin that can be used in the present invention, astaxanthin derived from Haematococcus algae is preferred from the viewpoint of ease of use. Haematococcus (Haematococcus pluvialis) is a type of microalgae.
[0052] When the topical skin preparation of the present invention contains an antioxidant (G1), its amount in the topical skin preparation is preferably 0.000001% by mass or more, in order to enhance the effects of the present invention by using the antioxidant (G1).From this viewpoint, the amount of the antioxidant (G1) in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more.Furthermore, from the same viewpoint, the amount of the antioxidant (G1) in the topical skin preparation is preferably 1% by mass or less, even more preferably 0.5% by mass or less, and particularly preferably 0.1% by mass or less.
[0053] When the topical skin preparation of the present invention contains an antioxidant (G1), the amount of the antioxidant (G1) is preferably 0.00005 to 0.2 parts by mass per 100 parts by mass of niacinamide (A), in order to improve the moisturizing effect and usability of the antioxidant (G1). From this perspective, the amount of the antioxidant (G1) is even more preferably 0.0002 parts by mass or more, and particularly preferably 0.0005 parts by mass or more, per 100 parts by mass of niacinamide (A). In order to further improve the effects of the present invention, the amount of the antioxidant (G1) is even more preferably 0.08 parts by mass or less, and particularly preferably 0.05 parts by mass or less, per 100 parts by mass of niacinamide (A).
[0054] The antioxidant (G1) may be encapsulated in a liposome containing the hydrogenated soybean phospholipid (F) as a membrane component, or may be present in the external aqueous phase outside the liposome, but is preferably present in the external aqueous phase.
[0055] (G2) Moisturizing agents include bilberry leaf extract; Phellodendron bark extract; hydrolyzed hyaluronic acid, acetylated hyaluronic acid, sodium hyaluronate; 2-methacryloyloxyethyl phosphorylcholine-butyl methacrylate copolymer; heparinoids; isomerized sugars; proteoglycans; aminobutyric acid, and the like. Among these, bilberry leaf extract is particularly preferred from the viewpoint of enhancing moisturizing effects and usability. "Bilberry" (also known as Vaccinium myrtillus) may refer to the leaves of Vaccinium myrtillus L., a plant of the Ericaceae family and Vaccinium genus. Alternatively, the leaves of Vaccinium smallii A. Gray var. glabrum Koidz., a plant of the same genus, may also be used. Furthermore, as long as the extract contains leaves, it may also contain other parts such as stems and flowers.
[0056] The bilberry leaf extract may be obtained by squeezing an extract containing the leaves of a plant, either directly or after crushing, or by extracting the leaves with a solvent, either directly or after crushing. The extraction solvent may be water, a hydrophilic organic solvent, or a water-containing hydrophilic organic solvent. Examples of hydrophilic organic solvents include lower aliphatic alcohols having 1 to 3 carbon atoms, such as methanol, ethanol, propanol, and isopropanol, and polyhydric alcohols having 2 to 4 carbon atoms, such as 1,3-butylene glycol, propylene glycol, and glycerin.
[0057] When the topical skin preparation of the present invention contains a moisturizing agent (G2), its amount is preferably 0.000001% by mass or more in the topical skin preparation, in order to ensure excellent antioxidant and other effects due to the use of the moisturizing agent (G2).From this perspective, the amount of the moisturizing agent (G2) in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more.Furthermore, from the same perspective, the amount of the moisturizing agent (G2) in the topical skin preparation is preferably 1% by mass or less, even more preferably 0.5% by mass or less, and particularly preferably 0.1% by mass or less.
[0058] When the topical skin preparation of the present invention contains a humectant (G2), the amount of the humectant (G2) is preferably 0.0001 to 0.2 parts by mass per 100 parts by mass of niacinamide (A), in order to further improve the effects of the present invention. From this perspective, the amount of the humectant (G2) is even more preferably 0.0005 parts by mass or more, and particularly preferably 0.001 parts by mass or more, per 100 parts by mass of niacinamide (A). From the viewpoint of further improving the effects of the present invention, the amount of the humectant (G2) is even more preferably 0.1 parts by mass or less, and particularly preferably 0.02 parts by mass or less, per 100 parts by mass of niacinamide (A). Each amount of (G2) above can be the amount of solid content.
[0059] The moisturizing agent (G2) may be encapsulated in liposomes containing the hydrogenated soybean phospholipid (F) as a membrane component, or may be present in the external aqueous phase outside the liposomes, but is preferably present in the external aqueous phase.
[0060] Examples of (G3) anti-inflammatory agents include dipotassium glycyrrhizinate, stearyl glycyrrhetinate, Centella asiatica leaf extract, and allantoin, with Centella asiatica leaf extract being particularly preferred from the viewpoint of enhancing moisturizing effect and usability. Centella asiatica leaf extract is an extract of Centella asiatica (Centella Asiatica) leaves. Centella asiatica leaf extract may be one that uses other parts of Centella asiatica, such as flowers or stems, in addition to Centella asiatica leaves. Centella asiatica leaf extract can be obtained by extracting Centella asiatica leaves as they are, or dried, crushed, or crushed and squeezed leaves with an extraction solvent. As the extraction solvent, water (including hot water), alcohols such as methanol, ethanol, isopropanol, ethylene glycol, propylene glycol, butylene glycol, glycerin, etc., esters such as ethyl acetate, ketones such as acetone and methyl ethyl ketone, nitriles such as acetonitrile, ethers such as diethyl ether and tetrahydrofuran, saturated hydrocarbons such as pentane, hexane, cyclopentane, cyclohexane, aromatic hydrocarbons such as toluene, halogenated hydrocarbons such as dichloromethane and chloroform, and other organic solvents such as dimethylformamide and dimethyl sulfoxide (which may all contain water), can be used appropriately, and any mixture of one or two of them can also be used. As the extraction solvent, alcohols are preferred, and ethanol, propylene glycol, and butylene glycol are more preferred.
[0061] When the topical skin preparation of the present invention contains an anti-inflammatory agent (G3), its amount is preferably 0.000001% by mass or more in the topical skin preparation, in order to enhance the antioxidant and other effects of the anti-inflammatory agent (G3).From this perspective, the amount of the anti-inflammatory agent (G3) in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more.Furthermore, from the same perspective, the amount of the anti-inflammatory agent (G3) in the topical skin preparation is preferably 1% by mass or less, even more preferably 0.5% by mass or less, and particularly preferably 0.3% by mass or less.
[0062] When the topical skin preparation of the present invention contains an anti-inflammatory agent (G3), the amount thereof is preferably 0.1 to 25 parts by mass per 100 parts by mass of niacinamide (A), in terms of improving the moisturizing effect and the feeling of use. From this viewpoint, the amount of the anti-inflammatory agent (G3) is even more preferably 0.2 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 100 parts by mass of niacinamide (A). From the viewpoint of further improving the effects of the present invention, the amount of the anti-inflammatory agent (G3) is even more preferably 20 parts by mass or less, and particularly preferably 10 parts by mass or less, per 100 parts by mass of niacinamide (A). The amount of each of the above-mentioned (G3) components can be the amount of solid content.
[0063] The anti-inflammatory agent (G3) may be encapsulated in a liposome containing the hydrogenated soybean phospholipid (F) as a membrane component, or may be present in the external aqueous phase outside the liposome, but is preferably present in the external aqueous phase.
[0064] Examples of (G4) skin whitening agents include ascorbic acid derivatives such as ascorbic acid, 3-laurylglyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, bisglyceryl ascorbic acid, 3-glyceryl ascorbic acid, ascorbyl palmitate phosphate trisodium, ascorbyl tetrahexyldecanoate, L-ascorbic acid 2-glucoside, magnesium ascorbyl phosphate, and sodium ascorbyl phosphate; tranexamic acid, hydroquinone, arbutin, placenta extract, kojic acid, etc. Among these, ascorbic acid derivatives are preferred, and bisglyceryl ascorbic acid is particularly preferred from the viewpoint of enhancing the moisturizing effect and the feeling of use.
[0065] When the topical skin preparation of the present invention contains a whitening agent (G4), its amount is preferably 0.000001% by mass or more in terms of solid content in the topical skin preparation, in order to ensure excellent effects such as improving transparency by using the whitening agent (G4). From this perspective, the amount of Centella asiatica leaf extract in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more. From the same perspective, the amount of the whitening agent (G4) in the topical skin preparation is preferably 1% by mass or less, even more preferably 0.5% by mass or less, and particularly preferably 0.1% by mass or less.
[0066] When the topical skin preparation of the present invention contains a whitening agent (G4), the amount thereof is preferably 0.1 to 25 parts by mass (solid content) per 100 parts by mass of niacinamide (A), in order to improve the moisturizing effect and the effect of improving the feel during use. From this viewpoint, the amount of the whitening agent (G4) is even more preferably 0.2 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 100 parts by mass of niacinamide (A). From the viewpoint of further improving the effects of the present invention, the amount of the whitening agent (G4) is even more preferably 20 parts by mass or less, and particularly preferably 10 parts by mass or less, per 100 parts by mass of niacinamide (A).
[0067] The (G4) whitening agent may be encapsulated in a liposome containing (F) hydrogenated soybean phospholipid as a membrane component, or may be present in the external aqueous phase outside the liposome, but is preferably present in the external aqueous phase.
[0068] (G5) Vitamins include salts and derivatives of vitamins A, B, E, and P, such as biotin, calcium pantothenate, tocopherol, tocopherol acetate, sodium tocopheryl phosphate, retinol, retinol palmitate, retinol acetate, retinol propionate, retinol linoleate, hydrogenated retinol, cyanocobalamin, folic acid, glucosyl hesperidin, and pyridoxine hydrochloride. Among these, tocopherol is preferred in terms of moisturizing effect and feeling in use. The tocopherol may be any of α, β, γ, and δ tocopherol.
[0069] When the topical skin preparation of the present invention contains (G5) vitamins, the amount thereof is preferably 0.000001% by mass or more in terms of solid content in the topical skin preparation, in order to ensure excellent antioxidant and other effects due to the use of (G5) vitamins. From this perspective, the amount of (G5) vitamins in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more. From the same perspective, the amount of (G5) vitamins in the topical skin preparation is preferably 1% by mass or less, even more preferably 0.5% by mass or less, and particularly preferably 0.2% by mass or less.
[0070] When the topical skin preparation of the present invention contains (G5) vitamins, the amount of (G5) vitamins is preferably 0.1 to 25 parts by mass per 100 parts by mass of (A) niacinamide, in order to improve the moisturizing effect and the effect of improving the feeling of use. From this viewpoint, the amount of (G5) vitamins is even more preferably 0.2 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 100 parts by mass of (A) niacinamide. In order to further improve the effects of the present invention, the amount of (G5) vitamins is even more preferably 20 parts by mass or less, and particularly preferably 10 parts by mass or less, per 100 parts by mass of (A) niacinamide.
[0071] The (G5) vitamins may be encapsulated in liposomes containing (F) hydrogenated soybean phospholipid as a membrane component, or may be present in the external aqueous phase outside the liposomes, but are preferably present in the external aqueous phase.
[0072] As the peeling agent (G6), organic acids are preferred, such as lactic acid, salicylic acid, glycolic acid, malic acid, mandelic acid, and lactobionic acid, with lactic acid being particularly preferred in terms of its moisturizing effect and feel when used.
[0073] When the topical skin preparation of the present invention contains a peeling agent (G6), its amount in the topical skin preparation is preferably 0.000001% by mass or more, in order to ensure excellent peeling effects and the like due to the use of the peeling agent.From this viewpoint, the amount of the peeling agent (G6) in the topical skin preparation is even more preferably 0.000005% by mass or more, and particularly preferably 0.00001% by mass or more.Furthermore, from the same viewpoint, the amount of the peeling agent (G6) in the topical skin preparation is preferably 1% by mass or less, even more preferably 0.5% by mass or less, and particularly preferably 0.2% by mass or less.
[0074] When the topical skin preparation of the present invention contains a peeling agent (G6), the amount of the peeling agent (G6) is preferably 0.1 to 25 parts by mass per 100 parts by mass of niacinamide (A), in order to improve the moisturizing effect and the feeling of use. From this viewpoint, the amount of the peeling agent (G6) is even more preferably 0.2 parts by mass or more, and particularly preferably 0.5 parts by mass or more, per 100 parts by mass of niacinamide (A). From the viewpoint of further improving the effects of the present invention, the amount of the peeling agent (G6) is even more preferably 20 parts by mass or less, and particularly preferably 10 parts by mass or less, per 100 parts by mass of niacinamide (A).
[0075] The peeling agent (G6) may be encapsulated in liposomes containing the hydrogenated soybean phospholipid (F) as a membrane component, or may be present in the external aqueous phase outside the liposomes, but is preferably present in the external aqueous phase.
[0076] The at least one selected from (G) antioxidants, (G2) moisturizers, (G3) anti-inflammatory agents, (G4) whitening agents, (G5) vitamins, and (G6) peeling agents is preferably one or more selected from (g1) astaxanthin, (g2) bilberry leaf extract, (g3) Centella asiatica leaf extract, (g4) bisglyceryl ascorbic acid, (g5) tocopherol, and (g6) lactic acid, and in particular, the inclusion of bilberry leaf extract is preferred in terms of increasing the moisture content of the stratum corneum. It is also preferable to contain all of (G1) antioxidant, (G2) moisturizer, (G3) anti-inflammatory agent, (G4) whitening agent, (G5) vitamins, and (G6) peeling agent, and it is particularly preferable to contain all of (g1) astaxanthin, (g2) bilberry leaf extract, (g3) Centella asiatica leaf extract, (g4) bisglyceryl ascorbic acid, (g5) tocopherol, and (g6) lactic acid, as this not only significantly enhances the moisturizing effect but also provides excellent and remarkable smoothness upon application and transparency and firmness of the skin after use.
[0077] In addition to the above-mentioned components, topical skin preparations may contain (H) other components. Examples of other components include components commonly used in topical skin preparations, such as organic solvents, sterols, oils other than sterols, thickeners, chelating agents, pH adjusters, fragrances, surfactants, and preservatives. Examples of organic solvents include the organic solvents used to prepare the phospholipid solution listed above, or in addition to these organic solvents, monohydric alcohols having 4 or less carbon atoms, such as ethanol, 2-propanol (isopropyl alcohol), butanol, and isobutyl alcohol; dihydric alcohols having 5 to 12 carbon atoms, such as propylene glycol, 1,3-butylene glycol, pentylene glycol, isopentyl diol, diethylene glycol, dipropylene glycol, ethylhexylglycerin, 1,3-propanediol, 1,5-pentanediol, 1,2-hexanediol, 1,2-octanediol, and 1,2-decanediol; diethylene glycol monoethyl ether; Examples of suitable alcohols include glycol ethers such as ethylene glycol monoethyl ether (ethoxydiglycol), ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, triethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol dibutyl ether, propylene glycol monoethyl ether, and dipropylene glycol monoethyl ether; glycol ether esters such as ethylene glycol monoethyl ether acetate, diethylene glycol monoethyl ether acetate, and propylene glycol monoethyl ether acetate; and glycol esters such as diethoxyethyl succinate and ethylene glycol disuccinate. Among these, the use of a dihydric alcohol having 5 to 12 carbon atoms is preferred in terms of moisturizing properties, feel during use, and bacteriostasis, and the use of 1,3-butylene glycol and / or pentylene glycol is particularly preferred.
[0078] From the viewpoints of smoothness, moisturizing properties, and bacteriostasis during use, the amount of organic solvent in the topical skin preparation is preferably 1 to 35% by mass, more preferably 3 to 25% by mass. When 1,3-butylene glycol and / or pentylene glycol is used, the amount of pentylene glycol is preferably 10 to 50 parts by mass per 100 parts by mass of 1,3-butylene glycol.
[0079] Examples of sterols include those contained as components of the membrane containing (F) hydrogenated soybean phospholipid. For example, liposomes may contain a sterol in addition to (F) hydrogenated soybean phospholipid as a membrane component. A topical skin preparation having such a configuration stabilizes the liposome membrane, thereby more easily achieving the moisturizing effect, smoothness upon application, transparency after use, and firming effect achieved by the combination of (C), (D), and (E) described above. Examples of sterols include cholesterol and phytosterols, with phytosterols being preferred in terms of usability and liposome stability. Phytosterol is a general term for sterols contained in plants, and known major components include β-sitosterol, stigmasterol, campesterol, brassicasterol, etc. The sterol may also be a mixture of multiple sterols.
[0080] When a sterol is contained, the content of the sterol in the topical skin preparation is preferably 0.01% by mass or more, from the viewpoint of more successfully obtaining a liposome membrane with an excellent encapsulation rate of components (C) to (E), more preferably 0.04% by mass or more, and particularly preferably 0.08% by mass or more. Furthermore, when a sterol is contained, the content of the sterol in the topical skin preparation is preferably 10% by mass or less, from the viewpoint of easily obtaining an topical skin preparation that is smooth in use and has excellent skin penetration, and from the viewpoint of good liposome stability, more preferably 5% by mass or less, and even more preferably 3% by mass or less. When a sterol is added in the above-mentioned liposome production process, the sterol is preferably added to the phospholipid solution used to prepare the liposomes, or at the timing of mixing the hydrogenated soybean phospholipid and the encapsulated components, from the viewpoint of the encapsulation rate and the texture of use and the stability of the liposomes.
[0081] Oils include vegetable oils such as safflower oil, soybean oil, evening primrose oil, grape seed oil, rosehip oil, kukui nut oil, almond oil, sesame oil, wheat germ oil, corn oil, cottonseed oil, avocado oil, olive oil, camellia oil, persic oil, castor oil, peanut oil, hazelnut oil, macadamia nut oil, and medfoam oil; animal oils such as squalane; hydrocarbon oils such as liquid paraffin, liquid isoparaffin, and petrolatum; ethyl oleate, ethyl linoleate, and myristyl alcohol. Isopropyl palmitate, isopropyl isostearate, isopropyl lanolinate, hexyl laurate, myristyl myristate, cetyl myristate, octyldodecyl myristate, decyl oleate, octyldodecyl oleate, hexyldecyl dimethyl octanoate, cetyl octanoate, isocetyl octanoate, cetostearyl octanoate, stearyl octanoate, isostearyl octanoate, cetyl palmitate, cetyl lactate, Examples of the oil include ester oils such as diisostearyl malate, dioctyl succinate, glyceryl tricaprylate, glyceryl tri-2-ethylhexanoate (triethylhexanoin), glyceryl trilaurate, glyceryl tripalmitate, glyceryl tristearate, glyceryl trioxystearate, glyceryl triisostearate, glyceryl trioleate, glyceryl triundecylenate, glyceryl tribehenate, glycerin trimyristate, tri(caprylic / capric acid)glycerin, propylene glycol dicaprylate, propylene glycol dicaprate, propylene glycol dinonanoate, propylene glycol di(caprylic / capric acid), propylene glycol distearate, propylene glycol diisodistearate, and propylene glycol dioleate; and silicone oils such as cyclic silicone, methylphenyl silicone, and dimethicone, from which one or more can be selected and used. In particular, it is preferable to use an ester oil and / or a silicone oil. As the ester oil, glyceryl tri-2-ethylhexanoate is preferable, and as the silicone oil, dimethicone is preferable.
[0082] When the topical skin preparation contains the oil, its content is preferably 0.5% by mass or more and 30% by mass or less, and more preferably 1% by mass or more and 20% by mass or less, in terms of the feel when used. When the topical skin preparation contains an ester oil and a silicone oil in combination, the preferred mass ratio of the two is 0.1 to 60 parts by mass of silicone oil per 100 parts by mass of ester oil.
[0083] Examples of thickeners include various types of thickeners that can be used in the fields of cosmetics and pharmaceuticals, such as natural polysaccharides, cellulose-based polymers, synthetic polymers, and clay minerals.
[0084] Examples of natural polysaccharides include polysaccharides derived from animals and plants or from microbial fermentation, such as xanthan gum, succinoglycan, carrageenan, guar gum, locust bean gum, galactan, gum arabic, tragacanth gum, tamarind gum, agar, agarose, mannan, curdlan, alginic acid or a salt thereof, gum arabic, pectin, quince seed, starch, algae colloid, chondroitin sulfate or a salt thereof, chitosan and its derivatives, nucleic acids or a salt thereof, ribonucleic acid or a salt thereof, water-soluble proteins such as casein, collagen, gelatin, albumin, fibroin, elastin, keratin, and sericin, and mucopolysaccharides such as hyaluronic acid or a salt thereof and chondroitin sulfate. Among these, xanthan gum is preferred in terms of usability.
[0085] Cellulose-based polymers are polymers composed of units of cellulose or its derivatives. Specific examples include carboxymethyl cellulose or its salts, methyl cellulose, ethyl cellulose, propyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, and sulfonated cellulose derivatives.
[0086] Synthetic polymers are polymers artificially synthesized using monomers as structural units. Specific examples include vinyl polymers such as carboxyvinyl polymers and polyvinyl alcohol, acrylic acid polymers such as acrylic acid / alkyl methacrylate copolymers, acrylates / alkyl acrylate crosspolymers and polyacrylic acid, acrylamide polymers such as polyacrylamide and polyalkylacrylamide / polyacrylamide copolymers, and (PEG-240 / decyltetradeceth-20 / HDI) copolymers. Among these, carboxyvinyl polymers and acrylic acid / alkyl methacrylate copolymers are preferred from the viewpoint of usability.
[0087] Clay minerals are substances commonly known as the main component minerals that make up clay, such as laponite, bentonite, smectite kaolinite, and montmorillonite.
[0088] In the present invention, it is preferable to use natural polysaccharides and / or synthetic polymers.
[0089] The amount of the thickener in the topical skin preparation is preferably 0.1 to 3% by mass. When a natural polysaccharide and a synthetic polymer are combined, the mass ratio of the two is preferably 100 parts by mass of the natural polysaccharide to 50 to 350 parts by mass of the synthetic polymer.
[0090] Examples of antibacterial and antiseptic agents include parabens (hydroxybenzoic acid esters) such as methylparaben, ethylparaben, propylparaben, and butylparaben; phenoxyethanol; alkyl glyceryl ethers such as 2-ethylhexylglyceryl ether (ethylhexylglycerin); salicylic acid; lanolin fatty acids and salts thereof; sodium benzoate; isothiazolinone derivatives such as methylchloroisothiazolinone and methylisothiazolinone; imidazolinium urea; dehydroacetic acid and salts thereof; phenols; and haloacillus acid salts such as triclosan. Examples of suitable organic solvents include fluorinated bisphenols, acid amides, and quaternary ammonium salts; trichlorocarbanide, zinc pyrithione, benzalkonium chloride, benzethonium chloride, sorbic acid, chlorhexidine, chlorhexidine gluconate, halocarban, hexachlorophene, and hinokitiol; other phenols such as phenol, isopropylphenol, cresol, thymol, parachlorophenol, phenylphenol, and sodium phenylphenol; phenylethyl alcohol, photosensitizers, antibacterial zeolites, and silver ions. 1,2-alkanediols such as pentylene glycol can also be used as antibacterial and antiseptic agents. When 1,2-alkanediols are used in the topical skin preparation of the present invention, the amount of the 1,2-alkanediol is included in the amount of the organic solvent, but is not included in the amount of the antibacterial and antiseptic agent described below.
[0091] The amount of the antibacterial / antiseptic agent in the external preparation for skin is preferably 0.01 to 1% by mass, more preferably 0.05 to 0.5% by mass.
[0092] Examples of chelating agents include edetates (ethylenediaminetetraacetates) such as EDTA, EDTA 2Na, EDTA 3Na, and EDTA 4Na; hydroxyethylethylenediaminetriacetates such as EDTA 3Na; pentetates (diethylenetriaminepentaacetate); phytic acid; phosphonic acids such as etidronic acid and salts thereof such as sodium salts; sodium oxalate; polyamino acids such as polyaspartic acid and polyglutamic acid; sodium polyphosphate, sodium metaphosphate, phosphoric acid; sodium citrate, and citric acid.
[0093] The amount of the chelating agent in the external preparation for skin is preferably 0.008 to 1% by mass, more preferably 0.01 to 0.5% by mass.
[0094] Preferred examples of the pH adjuster, acid, or alkali include acetic acid, sodium acetate, hydrochloric acid, sulfuric acid, monoethanolamine, diethanolamine, triethanolamine, isopropanolamine, triisopropanolamine, 2-amino-2-methyl-1,3-propanediol, 2-amino-2-hydroxymethyl-1,3-propanediol, arginine, sodium hydroxide, potassium hydroxide, aqueous ammonia, guanidine carbonate, and ammonium carbonate.
[0095] Although not limited thereto, the amount of water is preferably 40 to 90% by mass in the external preparation for skin.
[0096] The types of the external skin preparation of the present invention include hair cosmetics, skin cosmetics, makeup cosmetics, fragrance cosmetics, body cosmetics, etc. The external skin preparation of the present invention can be produced according to a conventional method.
[0097] To explain the types of topical skin preparations of the present invention in more detail, preferred examples of hair cosmetics include shampoos such as oil shampoo, cream shampoo, conditioning shampoo, anti-dandruff shampoo, hair color shampoo, and rinse-in-one shampoo; hair care agents such as rinse, conditioner, treatment, hair pack, hair mist, and hair oil; hair styling products such as hair foam, hair mousse, hair spray, hair wax, hair gel, hair cream, water grease, setting lotion, pomade, and tic; hair dyes such as color lotions, hair color treatments, hair manicures, and oxidation hair dyes; hair tonics, hair liquids, hair blow dryers, split end coats, permanent wave agents, straight perm agents, hair bleach, hair color pre-treatments, hair color after-treatments, perm pre-treatments, perm after-treatments, and hair growth agents.
[0098] Skin cosmetics include lotions such as softening lotion, astringent lotion, cleansing lotion, multi-layered lotion, and liposome lotion; emulsions such as emollient lotion, moisture lotion, milky lotion, nourishing lotion, nourishing milk, skin moisture, moisturizing emulsion, massage lotion, exfoliating smoother, elbow lotion, hand lotion, and body lotion; emollient cream, nourishing cream, nourishing cream, vanishing cream, moisture cream, night cream, massage cream, cleansing cream, makeup cream, base cream, pre-makeup cream, sunscreen cream, suntan cream, hair removal cream, deodorant cream, and shaving cream. gels such as moisturizing gels, whitening gels, and all-in-one gels; beauty serums such as moisturizing essences, whitening essences, moisturizing serums, and whitening serums; sunscreens such as sun protectants, sun protectors, UV care milks, and sunscreens; packs and masks such as peel-off packs, powder packs, washing packs, oil packs, and cleansing masks; makeup removers such as cleansing foams, cleansing creams, cleansing milks, cleansing lotions, cleansing gels, and cleansing oils; and facial cleansers such as paste facial cleansers, gel facial cleansers, foam facial cleansers, facial cleansing powders, cosmetic soaps, transparent soaps, medicated soaps, liquid soaps, and shaving soaps.
[0099] Preferred examples of makeup cosmetics include lipstick, lip gloss, foundation, blush, face powder, concealer, eyeliner, mascara, eye shadow, eyebrow pencil, nail enamel, enamel remover, and nail treatment.
[0100] Preferred examples of the aromatic cosmetics include perfumes, perfumes, parfums, eau de parfum, eau de toilette, eau de cologne, solid perfumes, aromatic powders, perfumed soaps, body lotions, and bath oils.
[0101] Preferred examples of body cosmetics include body cleansers such as body shampoos, deodorant cosmetics such as deodorant lotions, deodorant powders, deodorant sprays and deodorant sticks, bleaches, depilatories, bath additives, and insect repellents such as insect repellent sprays.
[0102] Among these, the types of external skin preparations of the present invention are preferably lotions, emulsions, creams, gels, beauty serums, packs, makeup removers, facial cleansers, etc., in terms of their moisturizing effect and the effect of improving the feeling of use.
[0103] Preferred dosage forms of the topical skin preparation of the present invention include emulsion-type cosmetics such as oil-in-water (O / W) type, water-in-oil (W / O) type, W / O / W type, and O / W / O type, as well as oil-based cosmetics, solid cosmetics, liquid cosmetics, paste cosmetics, stick-type cosmetics, volatile oil-type cosmetics, powder cosmetics, jelly-type cosmetics, gel-type cosmetics, paste-type cosmetics, emulsified polymer-type cosmetics, sheet-type cosmetics, mist-type cosmetics, and spray-type cosmetics. When the topical skin preparation of the present invention is an emulsion, the continuous phase may be either an aqueous phase or an oil phase. In the examples described below, compositions having an aqueous phase as the continuous phase are prepared.
[0104] The present invention will be described below based on examples, but the present invention is not limited to the following examples. In each example and comparative examples 1 to 5, the average particle size of the liposomes was 100 to 150 nm.
[0105] <Test Substances> (A) Niacinamide with a purity of 98% by mass or more was used. (B) D-Pantothenyl alcohol with a purity of 98% by mass or more was used. (C) 3-O-Ethyl ascorbic acid with a purity of 95% by mass was used. (D) A hot water extract (dried powder) of French maritime pine bark was used as the pine bark extract.
[0106] (E1) Reduced glutathione with a purity of 98% by mass or more was used, and (E2) N-stearoylphytosphingosine (ceramide NP) was used as ceramide.
[0107] (F) Hydrogenated soybean phospholipid: Hydrogenated soybean lecithin (purity 100% by mass) was used. (g2) As the bilberry leaf extract, a powder extracted using water and 1,3-butylene glycol in a 1:1 mass ratio as the extraction solvent was used. The purity was 0.2% by mass, with the remainder being water and 1,3-butylene glycol. (g1) As the astaxanthin, derived from Haematococcus algae, the purity was 50% by mass, with the remainder being glyceryl tri(caprylate / caprate). (g3) As the Centella asiatica leaf extract, a purified extract with a purity of 100% by mass was used. (g4) As the bisglyceryl ascorbic acid, one with a purity of 50% by mass was used. The remainder was water and glycerin. (g5) As the tocopherol, natural tocopherol with a purity of 100% by mass was used. (g6) As the lactic acid, one with a purity of 90% by mass was used. The remainder is water.
[0108] (H1) Phytosterol: 100% by mass purity was used. (H2) BG (1,3-butylene glycol) (H3) Pentylene glycol (H4) Triethylhexanoin (H5) Dimethicone (H6) Xanthan gum (H7) Carboxyvinyl polymer (H8) Potassium hydroxide (H9) EDTA-2Na (H10) Phenoxyethanol (H11) A woody fragrance was used. (H12) Water
[0109] (Example 1) The components used were (A) to (D), (E1), (E2), (F), and (H1) to (H12). (Step 1: Preparation of Liposomes) Of the above components, (F), (H1), and (H3) were mixed at 85°C (Liquid 1). Mixing was performed by adding (H1) and (H3) to (F) in that order. Furthermore, of the above components, (C), (D), (E1), and (E2) were mixed with (H12) in an amount corresponding to 13% by mass of the total amount of the topical skin preparation at 85°C (Liquid 2). Mixing was performed by adding (C) to (E) to (H12) in that order. Liquid 2 was added to Liquid 1, and the mixture was stirred at 85°C. A liposome dispersion was obtained through the above steps. (Step 2) The obtained liposome dispersion and the other pre-emulsified materials ((A), (B), (H2), (H4) to the remaining (H12)) were mixed by stirring at 45° C. As a result, a viscous liquid skin preparation for external use was obtained.
[0110] Examples 2 and 3 External skin preparations were obtained in the same manner as in Example 1, except that the amount of (A) niacinamide was changed and (E1) ceramide or (E2) glutathione was not used.
[0111] (Example 4) An external skin preparation was obtained in the same manner as in Example 1, except that the amount of (A) niacinamide was changed.
[0112] (Example 5) (g2) Bilberry leaf extract was added together with (A), (B), (H2), (H4) to (H12) in the second step. Except for this, an external skin preparation was obtained in the same manner as in Example 4.
[0113] Example 6: (g1) Astaxanthin, (g3) Centella asiatica leaf extract, (g4) bisglyceryl ascorbate, (g5) tocopherol, and (g6) lactic acid were added together with (A), (B), (H2), and (H4) to (H12) in Step 2. Except for this, a topical skin preparation was obtained in the same manner as in Example 5.
[0114] Comparative Examples 1 to 5 As shown in Table 1, external skin preparations were obtained in the same manner as in Example 4, except that (A), (B), (C), (D) or (E) was not used.
[0115] Comparative Example 6 A skin external preparation was obtained in the same manner as in Example 4, except that (F) hydrogenated soybean phospholipid and (H1) phytosterol were not used.
[0116] [Evaluation 1: Stratum corneum moisture content] Five professional monitors (healthy men and women in their 20s and 30s) were randomly selected as subjects. The inside of each subject's forearm was washed with facial cleanser and allowed to rest for 15 minutes in a measurement room. Next, the above-mentioned topical skin preparation was applied to a 4 cm x 4 cm area on the inside of the forearm and left to stand for 10 minutes. The topical skin preparation was then removed and the subject was washed with water. The stratum corneum moisture content (μS) was measured after washing. The results are shown in Table 1. The stratum corneum moisture content was measured using a skin epidermal stratum corneum moisture content measuring device, SKICON-200EX (manufactured by IBS). This skin epidermal stratum corneum moisture content measuring device evaluated the skin's conductance (electrical conductivity, unit: μS) as the moisture content of the stratum corneum. A higher stratum corneum moisture content value indicates a higher moisturizing effect.
[0117] [Evaluation 2: Usability] Five professional monitors (healthy men and women in their 20s and 30s) were randomly selected as test subjects. Each test subject washed the inside of their forearm with a facial cleanser and rested for 15 minutes in a measurement room. Next, the above-mentioned topical skin preparation was applied to a 4 cm x 4 cm area on the inside of the forearm. Evaluation items (3 items) after use were evaluated based on the following evaluation criteria. The evaluation results are shown in Table 1 below. The results below are the average of the evaluation scores of the five test subjects.
[0118] [Evaluation criteria] 5: Very good 4: Somewhat good 3: Standard 2: Somewhat poor 1: Very poor
[0119]
[0120] Preparation Examples 1 to 5 The serums described in Preparation Examples 1 to 5 were prepared in the same manner as in Example 1. As with the Examples, the serums of Preparation Examples 1 to 5 have excellent moisturizing effects, smoothness upon application, and excellent transparency and firmness of the skin after use.
[0121]
[0122] The topical skin preparation of the present invention has excellent moisturizing effect, smoothness upon application, and excellent transparency and firmness of the skin after use, and is therefore industrially useful.
Claims
1. A skin topical preparation comprising the following (A), (B), (C), (D), (E) and (F), wherein (C), (D) and (E) are encapsulated in liposomes containing (F) hydrogenated soybean phospholipid as a membrane component: (A) niacinamide; (B) D-pantothenyl alcohol; (C) 3-O-ethyl ascorbic acid; (D) pine bark extract; (E) at least one selected from glutathione and ceramides; and (F) hydrogenated soybean phospholipid.
2. The skin topical preparation according to claim 1, further comprising (G) at least one selected from the group consisting of antioxidants, moisturizing agents, anti-inflammatory agents, whitening agents, vitamins and peeling agents.
3. The external skin preparation according to claim 2, wherein (G) is one or more selected from the group consisting of bilberry leaf extract, astaxanthin, Centella asiatica leaf extract, bisglyceryl ascorbic acid, tocopherol and lactic acid.
4. A topical skin preparation described in any one of claims 1 to 3, wherein the content of (A) niacinamide is 5% by mass or more.
Citation Information
Patent Citations
Acerola seed extract-containing composition
JP2005220084A
Externally used preparation
JP2006193512A
Preparation for external use
JP2012201670A
Liposome dispersion liquid containing ceramides
JP2016160242A
Cosmetic or topical skin preparation containing 3-o-ethyl ascorbic acid
JP2023016083A
